Innovation Blossoms at CIIE: Roche Committed to Building a Leading Healthcare Ecosystem

Shanghai, October 29, 2020 /PRNewswire/ -- The third China International Import Expo (hereinafter referred to as the "CIIE") is scheduled to take place in Shanghai from November 5 to 10. Roche, a global leader in biotechnology, will once again showcase its pharmaceuticals and diagnostics divisions, offering an upgraded experience that is larger in scale, higher in quality, more innovative, and more dynamic. By doing so, Roche aims to build an industry-leading healthcare ecosystem and enhance the health and well-being of the Chinese people.

“The CIIE injects ‘Chinese momentum’ into promoting an open world economy and serves as the optimal platform for foreign enterprises to seize ‘China opportunities.’ Against the backdrop of the global pandemic spread and severe international economic and trade conditions, the on-schedule holding of the CIIE has demonstrated to the world China’s courage and determination to continuously advance high-level opening-up,” said Zhou Hong, President of Roche Pharmaceuticals China. “As a long-term partner of the CIIE, Roche continues to support the event as always. We look forward to leveraging the CIIE to ensure that Chinese patients benefit at the earliest opportunity from our globally leading innovative products and diagnostic and treatment solutions, thereby fulfilling our long-term commitment to patients in China through concrete actions.”

Diagnosis and Treatment Hand in Hand, Full-Course Protection, Leading the Future of Health

At this year’s China International Import Expo (CIIE), Roche Pharmaceuticals and Diagnostics jointly exhibited for the third time, comprehensively showcasing innovative products and whole-disease-management cases that span the entire lifecycle—from disease prevention, precise diagnosis and treatment, to disease management. Leveraging its integrated diagnostic-therapeutic innovation strengths and global expertise, Roche is committed to leading personalized medicine, tailoring integrated diagnostic and therapeutic solutions for Chinese patients, building a patient-centric healthcare ecosystem, and contributing to the grand vision of “Healthy China 2030.”

This philosophy is embedded in the very DNA of Roche’s booth design. At this year’s Roche booth, a blooming flower of innovation stands prominently, symbolizing “Partnering in Diagnostics and Treatment – Innovation Illuminates the Future.” Shimmering two-tone DNA double helices spiral upward from the center of the booth, with the genes of innovation deeply embedded within, instantly igniting the pulsating light of life. Roche Pharmaceuticals and Diagnostics will join hands to keep the flower of innovation in full bloom, providing comprehensive patient care throughout the entire journey and leading the way toward a healthier future.

Roche Booth Main Landmark Design Drawing

Roche Booth Main Landmark Design Drawing

# United in Overcoming Difficulties, Jointly Fighting the Epidemic

Amid the significant global public health challenges, Roche will showcase its prominent products and achievements in pandemic response at the inaugural “Public Health and Epidemic Prevention Zone” of this year’s China International Import Expo (CIIE). During the pandemic, Roche took immediate action, donating drugs, supplies, and cash totaling over RMB 28 million to support the Chinese government and healthcare institutions at all levels in the joint fight against the novel coronavirus.

Design Drawing of Roche’s Booth in the Public Health and Epidemic Prevention Zone

Rising to the Challenge: Accelerating Innovation

The sudden outbreak did not slow down Roche’s pace of innovative R&D. At this year’s China International Import Expo (CIIE), Roche will showcase a range of breakthrough innovative products, covering major disease areas such as cancer immunotherapy, influenza, hematologic malignancies, and rare diseases, thereby achieving a powerful combination of “innovation strength” and “China speed.”

Among them, the immunotherapy combination regimen used as first-line treatment for advanced unresectable hepatocellular carcinoma is the first in over a decadeThe first oneInnovative Therapies That Reduce Patient Mortality Risk，AlsoThe world's first and currently onlyThe immuno-oncology combination therapy approved for first-line treatment will provide Chinese liver cancer patients with novel therapeutic options; the first single-dose oral antiviral drug for influenza treatment requires only a single administration to effectively suppress the influenza virus within 24 hours, significantly reducing the duration of flu symptoms; innovative hematologic oncology drugs are expected to raise the five-year survival rate of lymphoma patients in China to levels comparable to those in developed Western countries.

Guided by the principle of “acting in response to patients’ needs first,” Roche has been deeply rooted in China for 26 years. Looking ahead, leveraging the high-level open platform of the China International Import Expo (CIIE), Roche will continue to strengthen its presence in the Chinese market, collaborate with partners across sectors to co-create, co-build, and share value, establish an industry-leading innovative healthcare ecosystem, and fulfill its long-term commitment of “being grounded in China and serving China.”

Note: This article involves innovative drugs and their indications that have not yet been officially approved in the Chinese market, for reference only. Please follow the advice or guidance of healthcare professionals.